Bridgewater headquartered Amneal Pharmaceuticals Inc, a global biopharmaceutical company, and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, announced that ...

MADRID, Dec. 22, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ: ...

The issuer is solely responsible for the content of this announcement. MADRID, Dec. 22, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, ...

At least one Big Apple resident was among 10 people hospitalized with “severe” illness in the US after injecting Botox bought from unlicensed sources through social media this year, officials said ...

(RTTNews) - Fresenius (FRE.DE) announced the launch of its denosumab biosimilars, Conexxence and Bomyntra, in Europe. The biosimilars received approval from the European Commission in July 2025 for ...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and ...

Wyost is approved for the treatment of cancer-related bone disease and Jubbonti is approved to treat osteoporosis. It builds on other key biosimilar launches this year including Wyost and Jubbonti in ...

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...

The FDA approved Stoboclo and Osenvelt as interchangeable biosimilars for Prolia and XGEVA, enhancing patient access and reducing costs. These biosimilars treat osteoporosis and bone mass loss in ...

Credit: Fresenius Kabi. Conexxence and Bomyntra were approved by the FDA in March 2025. The interchangeability designation allows the biosimilars to be substituted for the reference product at the ...

The FDA has approved two new drugs that are biosimilars to denosumab, adding to the ever-expanding field of less expensive options of the popular anti-osteoporosis and cancer-related bone loss drug; ...